Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 379

1.

Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms.

Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B.

Drug Alcohol Depend. 2007 Jan 5;86(1):22-9. Epub 2006 Jun 12.

PMID:
16769180
2.

Abstinence symptoms following oral THC administration to humans.

Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW.

Psychopharmacology (Berl). 1999 Feb;141(4):385-94.

PMID:
10090646
3.

Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans.

Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H.

Psychopharmacology (Berl). 2002 Jun;161(4):331-9. Epub 2002 Apr 19.

PMID:
12073159
4.

Marijuana withdrawal in humans: effects of oral THC or divalproex.

Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, Foltin RW.

Neuropsychopharmacology. 2004 Jan;29(1):158-70.

5.

Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study.

Winstock AR, Lea T, Copeland J.

J Psychopharmacol. 2009 Jan;23(1):84-93. doi: 10.1177/0269881108089584. Epub 2008 May 30.

PMID:
18515451
6.

Aspects of tolerance to and dependence on cannabis.

Wikler A.

Ann N Y Acad Sci. 1976;282:126-47.

PMID:
828472
7.

Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users.

Curran HV, Brignell C, Fletcher S, Middleton P, Henry J.

Psychopharmacology (Berl). 2002 Oct;164(1):61-70. Epub 2002 Jul 23.

PMID:
12373420
8.

Marijuana abstinence effects in marijuana smokers maintained in their home environment.

Budney AJ, Hughes JR, Moore BA, Novy PL.

Arch Gen Psychiatry. 2001 Oct;58(10):917-24.

PMID:
11576029
9.

Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study.

ElSohly MA, deWit H, Wachtel SR, Feng S, Murphy TP.

J Anal Toxicol. 2001 Oct;25(7):565-71.

PMID:
11599601
10.

Bupropion SR worsens mood during marijuana withdrawal in humans.

Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW.

Psychopharmacology (Berl). 2001 May;155(2):171-9.

PMID:
11401006
11.

Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.

Milman G, Bergamaschi MM, Lee D, Mendu DR, Barnes AJ, Vandrey R, Huestis MA.

Ther Drug Monit. 2014 Apr;36(2):218-24. doi: 10.1097/FTD.0b013e3182a5c446.

12.

Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC).

Hunault CC, Mensinga TT, Böcker KB, Schipper CM, Kruidenier M, Leenders ME, de Vries I, Meulenbelt J.

Psychopharmacology (Berl). 2009 May;204(1):85-94. doi: 10.1007/s00213-008-1440-0. Epub 2008 Dec 20.

PMID:
19099294
13.

Effects of oral THC maintenance on smoked marijuana self-administration.

Hart CL, Haney M, Ward AS, Fischman MW, Foltin RW.

Drug Alcohol Depend. 2002 Aug 1;67(3):301-9.

PMID:
12127201
14.

Prospective assessment of cannabis withdrawal in adolescents with cannabis dependence: a pilot study.

Milin R, Manion I, Dare G, Walker S.

J Am Acad Child Adolesc Psychiatry. 2008 Feb;47(2):174-8. doi: 10.1097/chi.0b013e31815cdd73.

PMID:
18176332
15.

Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.

Cannabis-In-Cachexia-Study-Group, Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T.

J Clin Oncol. 2006 Jul 20;24(21):3394-400.

PMID:
16849753
16.

Abstinence symptoms following smoked marijuana in humans.

Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW.

Psychopharmacology (Berl). 1999 Feb;141(4):395-404.

PMID:
10090647
17.

[Effects of oral cannabis and dronabinol on driving capacity].

Giroud C, Augsburger M, Favrat B, Menetrey A, Pin MA, Rothuizen LE, Appenzeller M, Buclin T, Mathieu S, Castella V, Hazekamp A, Mangin P.

Ann Pharm Fr. 2006 May;64(3):161-72. French.

PMID:
16710114
18.

Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle.

Niedbala RS, Kardos KW, Fritch DF, Kunsman KP, Blum KA, Newland GA, Waga J, Kurtz L, Bronsgeest M, Cone EJ.

J Anal Toxicol. 2005 Oct;29(7):607-15.

PMID:
16419389
19.

Evaluating the impact of hemp food consumption on workplace drug tests.

Leson G, Pless P, Grotenhermen F, Kalant H, ElSohly MA.

J Anal Toxicol. 2001 Nov-Dec;25(8):691-8.

PMID:
11765026
20.

Comparison of smoked marijuana and oral Delta(9)-tetrahydrocannabinol in humans.

Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW.

Psychopharmacology (Berl). 2002 Dec;164(4):407-15. Epub 2002 Sep 14.

PMID:
12457271

Supplemental Content

Support Center